[¹⁸F]-NOTA-FAPI-04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management

Abstract

A 47-year-old woman underwent [¹⁸F]-FDG and [¹⁸F]-NOTA-FAPI-04 PET/CT to assess the staging of suspected axillary lymph node enlargement following breastconserving surgery. The imaging with these two PET agents revealed starkly contrasting results. Significant [¹⁸F]-FDG uptake in the right axillary fossa, intrathoracic muscles, and clavicle lymph nodes led nuclear medicine physicians to suspect metastasis. However, no uptake of [¹⁸F]-NOTA-FAPI-04 was observed. Subsequently, the patient underwent an ultrasound-guided biopsy of the enlarged axillary lymph nodes, which pathologically confirmed the diagnosis as inflammation. After a multidisciplinary discussion, the patient received radiotherapy for the right breast and 2.15Gy/F×28F for the tumor bed. She was discharged following the completion of her radiotherapy. Accurate diagnosis and staging are pivotal in selecting the optimal clinical treatment for breast cancer patients. Notably, [¹⁸F]-NOTA-FAPI-04 PET/CT downgraded this patient’s staging, significantly influencing the treatment strategy.

Keywords

breast cancer / fibroblast activation protein / PET

References

[1] Paydary K, Seraj SM, Zadeh MZ, et al. The Evolving Role of FDGPET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol. 2019;21(1):1-10.

[2] Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267-274.

[3] Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5-6):454-463.

[4] Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59(9):1423-1429.

[5] Liu F, Qi L, Liu B, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One. 2015;10(3):e0116683.

[6] Sharma P, Singh SS, Gayana S. Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool. Clin Nucl Med. 2021;46(3):e141-e150.

[7] Sahin E, Kus T, Aytekin A, et al. 68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CTin the Imaging of Invasive LobularBreastCarcinoma. J Nucl Med. 2024;65(4):512-519.

[8] Backhaus P, Burg MC, Roll W, et al. Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer. Radiology. 2022;302(1):39-47.

[9] Yang L, Cheng L, Xu Y, et al. PET Imaging of Fibroblast Activation Protein in Various Cancers Using [18F]AlFNOTAFAPI04: Comparison with 18F-FDG in a Single-Center, Prospective Study. Acad Radiol. 2024;31(10):4107-4118.

[10] Wei Y, Zheng J, Ma L, et al. [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49(8):2761-2773.

[11] Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59(9):1423-1429.

[12] Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 1994;91(12):5657-5661.

[13] Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-7239.

[14] Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11(5):3203-3211.

[15] Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37(32):4343-4357.

[16] Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266(2):388-405.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.